162 related articles for article (PubMed ID: 11121733)
1. Can oral midazolam predict oral cyclosporine disposition?
Paine MF; Davis CL; Shen DD; Marsh CL; Raisys VA; Thummel KE
Eur J Pharm Sci; 2000 Nov; 12(1):51-62. PubMed ID: 11121733
[TBL] [Abstract][Full Text] [Related]
2. Prediction of cyclosporine clearance in liver transplant recipients by the use of midazolam as a cytochrome P450 3A probe.
Villeneuve JP; L'Ecuyer L; De Maeght S; Bannon P
Clin Pharmacol Ther; 2000 Mar; 67(3):242-8. PubMed ID: 10741627
[TBL] [Abstract][Full Text] [Related]
3. In vivo comparisons of constitutive cytochrome P450 3A activity assessed by alprazolam, triazolam, and midazolam.
Masica AL; Mayo G; Wilkinson GR
Clin Pharmacol Ther; 2004 Oct; 76(4):341-9. PubMed ID: 15470333
[TBL] [Abstract][Full Text] [Related]
4. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin.
Gorski JC; Jones DR; Haehner-Daniels BD; Hamman MA; O'Mara EM; Hall SD
Clin Pharmacol Ther; 1998 Aug; 64(2):133-43. PubMed ID: 9728893
[TBL] [Abstract][Full Text] [Related]
5. Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects.
Dresser GK; Schwarz UI; Wilkinson GR; Kim RB
Clin Pharmacol Ther; 2003 Jan; 73(1):41-50. PubMed ID: 12545142
[TBL] [Abstract][Full Text] [Related]
6. Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping.
Lee JI; Chaves-Gnecco D; Amico JA; Kroboth PD; Wilson JW; Frye RF
Clin Pharmacol Ther; 2002 Dec; 72(6):718-28. PubMed ID: 12496753
[TBL] [Abstract][Full Text] [Related]
7. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine.
Lown KS; Mayo RR; Leichtman AB; Hsiao HL; Turgeon DK; Schmiedlin-Ren P; Brown MB; Guo W; Rossi SJ; Benet LZ; Watkins PB
Clin Pharmacol Ther; 1997 Sep; 62(3):248-60. PubMed ID: 9333100
[TBL] [Abstract][Full Text] [Related]
8. In-vivo and in-vitro metabolic clearance of midazolam, a cytochrome P450 3A substrate, by the liver under normal and increased enzyme activity in rats.
Higashikawa F; Murakami T; Kaneda T; Takano M
J Pharm Pharmacol; 1999 Apr; 51(4):405-10. PubMed ID: 10385212
[TBL] [Abstract][Full Text] [Related]
9. The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity.
Gorski JC; Vannaprasaht S; Hamman MA; Ambrosius WT; Bruce MA; Haehner-Daniels B; Hall SD
Clin Pharmacol Ther; 2003 Sep; 74(3):275-87. PubMed ID: 12966371
[TBL] [Abstract][Full Text] [Related]
10. Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole.
Tsunoda SM; Velez RL; von Moltke LL; Greenblatt DJ
Clin Pharmacol Ther; 1999 Nov; 66(5):461-71. PubMed ID: 10579473
[TBL] [Abstract][Full Text] [Related]
11. Assessment of the hepatic and intestinal first-pass metabolism of midazolam in a CYP3A drug-drug interaction model rats.
Kanazu T; Okamura N; Yamaguchi Y; Baba T; Koike M
Xenobiotica; 2005 Apr; 35(4):305-17. PubMed ID: 16019953
[TBL] [Abstract][Full Text] [Related]
12. A urine metabolic ratio of dextromethorphan and 3-methoxymorphinan as a probe for CYP3A activity and prediction of cyclosporine clearance in healthy volunteers.
Min DI; Ku YM; Vichiendilokkul A; Fleckenstein LL
Pharmacotherapy; 1999 Jun; 19(6):753-9. PubMed ID: 10391422
[TBL] [Abstract][Full Text] [Related]
13. Relationship between hepatic cytochrome P450 3A content and activity and the disposition of midazolam administered orally.
Wandel C; Böcker RH; Böhrer H; deVries JX; Hofmann W; Walter K; Kleingeist B; Neff S; Ding R; Walter-Sack I; Martin E
Drug Metab Dispos; 1998 Feb; 26(2):110-4. PubMed ID: 9456296
[TBL] [Abstract][Full Text] [Related]
14. Relative bioavailability of Neoral versus Sandimmune in the presence of a P450IIIA and P-glycoprotein inhibitor.
Choc MG; Mueller EA; Robinson WT; Kumle A; Smith HT; Charnick SB
Transplant Proc; 1998 Aug; 30(5):1664-5. PubMed ID: 9723234
[No Abstract] [Full Text] [Related]
15. Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis.
Kharasch ED; Walker A; Hoffer C; Sheffels P
Clin Pharmacol Ther; 2004 Nov; 76(5):452-66. PubMed ID: 15536460
[TBL] [Abstract][Full Text] [Related]
16. Failure of erythromycin breath test to correlate with midazolam clearance as a probe of cytochrome P4503A.
Kinirons MT; O'Shea D; Kim RB; Groopman JD; Thummel KE; Wood AJ; Wilkinson GR
Clin Pharmacol Ther; 1999 Sep; 66(3):224-31. PubMed ID: 10511057
[TBL] [Abstract][Full Text] [Related]
17. Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xanthine oxidase with the "Cooperstown cocktail".
Streetman DS; Bleakley JF; Kim JS; Nafziger AN; Leeder JS; Gaedigk A; Gotschall R; Kearns GL; Bertino JS
Clin Pharmacol Ther; 2000 Oct; 68(4):375-83. PubMed ID: 11061577
[TBL] [Abstract][Full Text] [Related]
18. CYP3A activity in African American and European American men: population differences and functional effect of the CYP3A4*1B5'-promoter region polymorphism.
Wandel C; Witte JS; Hall JM; Stein CM; Wood AJ; Wilkinson GR
Clin Pharmacol Ther; 2000 Jul; 68(1):82-91. PubMed ID: 10945319
[TBL] [Abstract][Full Text] [Related]
19. Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism.
Paine MF; Khalighi M; Fisher JM; Shen DD; Kunze KL; Marsh CL; Perkins JD; Thummel KE
J Pharmacol Exp Ther; 1997 Dec; 283(3):1552-62. PubMed ID: 9400033
[TBL] [Abstract][Full Text] [Related]
20. Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone.
Kharasch ED; Hoffer C; Whittington D; Sheffels P
Clin Pharmacol Ther; 2004 Sep; 76(3):250-69. PubMed ID: 15371986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]